{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?q=PD-L1", "query": { "q": "PD-L1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1570, "total_pages": 157, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?q=PD-L1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T05:09:40.589Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03821792", "title": "Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Prostate Carcinoma Metastatic in the Bone", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2019-07-22", "completion_date": "2026-10-11", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821792" }, { "nct_id": "NCT05190445", "title": "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Gastric Cancer" ], "interventions": [ { "name": "Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel", "type": "DRUG" }, { "name": "Cinrebafusp alfa (PRS-343) in combination with tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pieris Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2021-11-01", "completion_date": "2023-02-01", "has_results": false, "last_update_posted_date": "2022-09-08", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 4, "location_summary": "Santa Barbara, California • Silver Spring, Maryland • New York, New York + 1 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05190445" }, { "nct_id": "NCT06061809", "title": "N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803", "type": "DRUG" }, { "name": "Tumor Treating Fields (TTFields, 200 kHz)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2024-08-07", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 4, "location_summary": "El Segundo, California • Fullerton, California • Newport Beach, California + 1 more", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06061809" }, { "nct_id": "NCT02963831", "title": "A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Ovarian Cancer", "Appendiceal Cancer" ], "interventions": [ { "name": "ONCOS-102", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2017-09-07", "completion_date": "2022-06-25", "has_results": true, "last_update_posted_date": "2022-12-22", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 6, "location_summary": "San Diego, California • Miami, Florida • Buffalo, New York + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02963831" }, { "nct_id": "NCT06732401", "title": "Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Echocardiography Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-08-07", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 193, "location_summary": "Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 164 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06732401" }, { "nct_id": "NCT03786692", "title": "Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Carcinoma of Lung, TNM Stage 4" ], "interventions": [ { "name": "Arm A", "type": "DRUG" }, { "name": "Arm B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2019-09-04", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03786692" }, { "nct_id": "NCT06754501", "title": "A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2025-04-11", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06754501" }, { "nct_id": "NCT02541604", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 87, "start_date": "2015-11-30", "completion_date": "2019-06-06", "has_results": true, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • Palo Alto, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02541604" }, { "nct_id": "NCT05077709", "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer Non Small Cell", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma Bladder" ], "interventions": [ { "name": "IO102-IO103 in combination with pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IO Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2022-04-11", "completion_date": "2026-02-08", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 9, "location_summary": "Duarte, California • Sacramento, California • San Diego, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Orange City", "state": "Florida" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077709" }, { "nct_id": "NCT02339558", "title": "Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Nonkeratinizing Carcinoma", "Recurrent Nasopharynx Carcinoma", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage IV Nasopharyngeal Carcinoma AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVC Nasopharyngeal Carcinoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2015-07-21", "completion_date": null, "has_results": true, "last_update_posted_date": "2019-09-13", "last_synced_at": "2026-07-24T05:09:40.589Z", "location_count": 15, "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02339558" } ] }